Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Med Trop (Mars) ; 55(4 Suppl): 41-6, 1995.
Article in English | MEDLINE | ID: mdl-8649265

ABSTRACT

Malaria, especially that due to Plasmodium falciparum, is one of the most important parasitic disease in man. It causes more than 400 million cases per year and between 1 to 3 million deaths, mainly among young children and pregnant women in sub-Saharan Africa. The current malaria control strategies using rapid diagnosis and treatment as well as methods to reduce the man-vector contact have had limited success. In Kilombero district (Southern Tanzania), malaria transmission is perennial (parasite prevalence > or = 80% all year) and intense (approximatively 300 infectious bites per year). At the household level, each under-5 child suffers on average 3 clinical fever episodes per year. Minimum estimated community rates for serious malaria (cerebral malaria or malaria and anaemia) affect approximatively 5% of all children. Under conditions of a field experiment, the annual incidence of a febrile illness (axillary temperature > or = 37.5 degrees C) reported to the curative primary health services in each child was 0.86 of which 0,35 can be attributed to Plasmodium falciparum malaria. The best estimate of the SPf66 vaccine protective efficacy in the Kilombero was 31% (95% CI : 0.52).


Subject(s)
Malaria Vaccines/administration & dosage , Malaria, Falciparum/prevention & control , Protozoan Proteins/administration & dosage , Recombinant Proteins , Child, Preschool , Female , Humans , Incidence , Infant , Infant, Newborn , Malaria Vaccines/immunology , Malaria, Falciparum/epidemiology , Malaria, Falciparum/parasitology , Male , Population Surveillance , Prevalence , Protozoan Proteins/immunology , Rural Health , Tanzania/epidemiology
2.
Lancet ; 344(8931): 1175-81, 1994 Oct 29.
Article in English | MEDLINE | ID: mdl-7934537

ABSTRACT

Effective, safe antimalarial vaccines have proved elusive. The synthetic polypeptide SPf66 vaccine is based on preerythrocytic and asexual blood-stage proteins of Plasmodium falciparum. We report here a randomised double-blind placebo-controlled trial of the efficacy of the SPf66 vaccine against clinical P falciparum malaria in idete, southern Tanzania, an area of intense perennial malaria transmission. 586 children aged 1-5 years received three doses of vaccine (n = 274) or placebo (n = 312). The incidence and density of parasitaemia were assessed through repeated cross-sectional surveys on subgroups of children. Morbidity was monitored over a 1 year period through passive case detection in all children plus active case detection in a subgroup of 191. An episode of clinical malaria was defined as measured fever (> or = 37.5 degrees C) and parasite density > 20,000/microL. No severe side-effects were seen and the frequency of mild side-effects after the third dose was less than 6%. The vaccine was highly immunogenic and after three doses all vaccine recipients had detectable anti-SPf66 antibodies: the geometric mean index of response was 8.3 in the vaccine group and 0.7 in the placebo group. The incidence of parasitaemia was similar in both groups. 123 children had at least one episode of clinical malaria during the follow-up period after the third dose and annual incidence rates were 0.25 in the vaccine group and 0.35 in the placebo group. Estimated vaccine efficacy was 31% (95% confidence interval 0-52%; p = 0.046). After the third dose there were 6 deaths among the study cohort (1 vaccine, 5 placebo). This study confirms that SPf66 is safe, immunogenic and reduces the risk of clinical malaria among children exposed to intense P falciparum transmission.


Subject(s)
Malaria Vaccines , Malaria, Falciparum/prevention & control , Protozoan Proteins , Recombinant Proteins , Vaccination , Child, Preschool , Cross-Sectional Studies , Double-Blind Method , Follow-Up Studies , Humans , Immunization Schedule , Infant , Informed Consent , Malaria Vaccines/administration & dosage , Malaria, Falciparum/immunology , Malaria, Falciparum/parasitology , Protozoan Proteins/administration & dosage , Tanzania/epidemiology
SELECTION OF CITATIONS
SEARCH DETAIL
...